Shield Therapeutics

Shield Therapeutics plc is registered in England and Wales. 

Default features description for sign up page.

Partnerships

Contact and Locations

Leadership

Overview

Webinars

Announcements

Media

ID/IDA Facts and Figures

Portfolio

Publications

Approved Medicine

Corporate Governance

AIM Rule 26

Analysts & Advisors

Financials

Stock Information

Investor Overview

Noto Sans

Shield Therapeutics CEO Anders Lundstrom and CFO Santosh Shanbhag joined Steve Darling from Proactice to share its released an unaudited Q3 2024 trading update revealing $7.2 million in net revenues from ACCRUFeR prescriptions, with an average net selling price of $167 per prescription. Excluding July's summer buying trends, the NSP averaged $192 in Q3, and Shield anticipates maintaining this level into Q4. Shield looks to gain traction, especially in the United States, where it partners with Viatris, deploying a sales force of 100 to promote ACCRUFeR.  To support its objective of achieving cash flow positivity by 2025, Shield has expanded its working capital financing with Sallyport Commercial Finance from $10 million to $15 million. Additionally,  Shanbhag also noted that steps are being taken to improve Shield’s cash position, including a planned 10% cost reduction and expanded financing from Sallyport, which he believes will support Shield’s objective of reaching cash flow positivity by the end of 2025.

Q3 Trading Update